bioAffinity Technologies Reports First Quarter 2023 Financial Results
Retrieved on:
Monday, May 15, 2023
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Patent, Use, Compensator (control theory), Journal of Visualized Experiments, Marketing, Respiratory Research, Clinical trial, Lung cancer, Receiver operating characteristic, Pulmonology, BIAF, Research, Lung, IPO, Flow cytometry, Treating, Patient, Physician, European, CFO, FDA, Therapy, Medical imaging, Medical device, Pharmaceutical industry, ROC
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other diseases of the lung, today reported financial results for the three months ended March 31, 2023.
Key Points:
- bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other diseases of the lung, today reported financial results for the three months ended March 31, 2023.
- Highlights from the first quarter of 2023 and subsequent weeks included:
Appointed Michael Dougherty as Chief Financial Officer. - Research and development expenses were $370,000 for the first quarter of 2023, compared with $280,000 for the comparable period in 2022.
- Clinical development expenses were $20,000 for the first quarter of 2023, compared with $53,000 for the first quarter of 2022.